Fa'amaonia e le FDA mo Togafitiga Fou ole ADHD i Tagata Matutua

A HOLD Fa'asa'oloto 5 | eTurboNews | eTN

Supernus Pharmaceuticals, Inc. na faʻasalalau e faʻamaonia e le US Food and Drug Administration (FDA) le faʻalauteleina o faʻamatalaga mo Qelbree (viloxazine extended-release capsules) mo le togafitiga o faʻamaʻi faʻamaʻi le atoatoa (ADHD) i tagata matutua matutua 18 tausaga ma matutua atu. Ua faamaonia nei e le FDA le Qelbree mo le togafitia o le ADHD i tamaiti (amata i le 6 tausaga), talavou ma tagata matutua.

E tusa ma le 16 miliona tamaiti, talavou, ma tagata matutua o loʻo i ai le ADHD i le US E ui o le tele o tamaiti e maua i le ADHD e sili atu i latou, e oʻo atu i le 90% oi latou e maua i le ADHD i le laiti o loʻo faʻaauau pea ona iai le ADHD i le avea ma tagata matutua.

"Seia oo mai i aso nei, o filifiliga ADHD e le faʻamalosia mo tagata matutua ua matua faʻatapulaʻaina," o le tala lea a Greg Mattingly, MD, paaga faʻavae a St. Charles Psychiatric Associates i St. Louis, Mo. "O lenei faʻatagaga o se tala lelei ma ofoina atu se filifiliga fou fou mo le le faitau miliona o tagata matutua Amerika o loʻo taumafai e suʻe togafitiga saʻo e pulea ai a latou faʻailoga ADHD."

O le Qelbree ose tala fou e le fa'amalositino e ave fa'atasi i aso uma mo le fa'aalia i le aso atoa. O le aoga ma le faʻaleleia o faʻamaoniga na matauina i le amataga o togafitiga. O lo'o i ai se fa'amaoniga saogalemu ma le fa'amalieina, e leai se fa'amaoniga o le fa'aleagaina i su'esu'ega falema'i. O le faʻatagaga e faʻavae i luga o faʻaiʻuga lelei mai se suʻesuʻega faʻafuaseʻi, lua tauaso, placebo-controlled Phase III suʻesuʻega a Qelbree i tagata matutua ma le ADHD ma faʻatusalia le faʻatagaina muamua o se tala e le faʻafefeteina togafitiga mo tagata matutua i le 20 tausaga.

"I le avea ai o se taʻitaʻi i le fanua o le CNS, matou te tuuto atoatoa i le malamalama atili i le auala e togafitia ai faʻamaʻi faʻalavelave e pei o le ADHD," o le tala lea a Jack Khattar, Peresitene ma Pule Sili o Supernus Pharmaceuticals. "O le faʻatagaina o aso nei o loʻo faʻailogaina ai se alualu i luma tele i togafitiga o le ADHD ma o se faʻailoga taua i le naʻo le tasi le tausaga talu ona faʻatagaina Qelbree e togafitia maʻi tamaiti. Matou te mitamita e aumai se tala fou e le faʻamalosia filifiliga mo tagata matutua i le maketi pe a maeʻa le luasefulu tausaga.

I le fa'avasegaina o aso ta'itasi i le va o le 200mg i le 600mg, o le vaega III fa'ata'ita'iga na fetaui ma le fa'ai'uga muamua e fa'aalia ai le fa'aitiitiga o le suiga mai le laina fa'avae o le Su'esu'ega ADHD Matutua Fa'ailoga Fa'ailoga Fa'ailoga (AISRS) togi atoa i le fa'ai'uga o su'esu'ega sa matua'i fa'afuainumera tele i tagata matutua. togafitia ile Qelbree versus placebo (p=0.0040). O le faʻaleleia atili o le AISRS subscale scores o le le faʻalogo ma le hyperactivity / impulsivity faʻailoga na matauina foi i le suʻesuʻega. E le gata i lea, o le suʻesuʻega na faʻafeiloaʻi ai le faʻaiʻuga o le aoga maualuga lona lua ma le taua o fuainumera (p = 0.0023) i le suiga mai le laina faʻavae o le Clinical Global Impression - Severity of Illness (CGI-S) Fua i le vaiaso 6. O le fualaau malosi na faʻafeiloaʻi lelei. Fa'amolemole va'ai nisi Fa'amatalaga Taua mo le Saogalemu o lo'o i lalo.

1 Qelbree na suʻesuʻeina ile 4 suʻesuʻega faʻapitoa. I se suʻesuʻega se tasi o tamaiti 6 i le 11 tausaga le matutua, o le ADHD faʻaitiitiga faʻaitiitiga faʻaitiitiga e taua tele mo 100 mg ma 200 mg doses, amata i le vaiaso 1. I le suʻesuʻega o talavou 12 i le 17 tausaga, o le ADHD faʻaitiitiga faʻaitiitiga faʻaitiitiga faʻafuainumera. taua mo le 400 mg, amata i le vaiaso 2. I le suʻesuʻeina o suʻesuʻega fetuutuunai a tagata matutua 18 i le 65 tausaga le matutua, o faʻaitiitiga faʻailoga o le ADHD na faʻamauina taua i tagata maʻi Qelbree, amata i le vaiaso 2.

FAʻAMATALAGA SAFETAI FAʻAMATALAGA

E mafai e Qelbree ona faʻateleina mafaufauga ma gaioiga pule, i tamaiti ma tagata matutua e iai le ADHD, aemaise lava i totonu o nai masina muamua o togafitiga poʻo pe a suia le vailaʻau. Ta'u i lau foma'i pe i ai (po'o i ai se tala'aga o lou aiga) ni mafaufauga po'o ni gaioiga e pule i le ola a'o le'i amataina le Qelbree. Mataʻituina ou lagona, amioga, mafaufauga, ma lagona i le taimi o togafitiga ma Qelbree. Lipoti so'o se suiga fou pe fa'afuase'i i nei fa'ailoga i le taimi lava lena. Qelbree e le tatau ona tagofia e tagata mamaʻi o loʻo inu nisi vailaʻau faʻamaʻi, aemaise lava i latou e taʻua o le monoamine oxidase inhibitor poʻo le MAOI, poʻo nisi vailaʻau fomaʻi.

OA MEA E AVEA MAI LENEI TUSI:

  • At a daily flexible-dose between 200mg to 600mg, the Phase III trial met the primary endpoint showing the reduction in the change from baseline of the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at end of study was statistically significantly greater in adults treated with Qelbree versus placebo (p=0.
  • The approval is based on positive results from a randomized, double blind, placebo-controlled Phase III study of Qelbree in adults with ADHD and represents the first approval of a novel nonstimulant treatment for adults in 20 years.
  • “Today’s approval marks a major advancement in the treatment of ADHD and is an important milestone just one year after the approval of Qelbree to treat pediatric patients.

E uiga i le tusitala

Linda Hohnholz

Faatonu sili mo eTurboNews fa'avae ile eTN HQ.

lesitala
Faasilasila i
mālō
0 faamatalaga
Manatu Faʻapena
Vaʻai manatu uma
0
E te alofa i ou mafaufauga, faamolemole taʻu mai.x
()
x
Fa'asoa i...